Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Rama Shivakumar"'
Autor:
Mark Gurney, Arwen Stikvoort, Emma Nolan, Lucy Kirkham-McCarthy, Stanislav Khoruzhenko, Rama Shivakumar, Sonja Zweegman, Niels W.C.J. van de Donk, Tuna Mutis, Eva Szegezdi, Subhashis Sarkar, Michael O’Dwyer
Publikováno v:
Haematologica, Vol 107, Iss 2 (2020)
There is a strong biological rationale for the augmentation of allogeneic natural killer (NK) cell therapies with a chimeric antigen receptor (CAR) to enhance acute myeloid leukemia (AML) targeting. CD38 is an established immunotherapeutic target in
Externí odkaz:
https://doaj.org/article/b0166d6551d14cd29eee673fac8c0c91
Autor:
Subhashis Sarkar, Eva Szegezdi, Emma Nolan, Sonja Zweegman, Lucy Kirkham-McCarthy, Stanislav Khoruzhenko, Niels W.C.J. van de Donk, Mark Gurney, Rama Shivakumar, Tuna Mutis, Arwen Stikvoort, Michael O'Dwyer
Publikováno v:
Gurney, M, Stikvoort, A, Nolan, E, Kirkham-McCarthy, L, Khoruzhenko, S, Shivakumar, R, Zweegman, S, van de Donk, N W C J, Mutis, T, Szegezdi, E, Sarkar, S & O'Dwyer, M 2020, ' CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide ', Haematologica, vol. Online ahead of print . https://doi.org/10.3324/haematol.2020.271908
Haematologica, Online ahead of print. Ferrata Storti Foundation
Haematologica, Online ahead of print. Ferrata Storti Foundation
There is a strong biological rationale for the augmentation of allogeneic natural killer (NK) cell therapies with a chimeric antigen receptor (CAR) to enhance acute myeloid leukemia (AML) targeting. CD38 is an established immunotherapeutic target in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae6bc215f1cb081e597341b9129c1216
https://research.vumc.nl/en/publications/6d9a8a41-bb5f-48ba-9f37-40dee1cc1e44
https://research.vumc.nl/en/publications/6d9a8a41-bb5f-48ba-9f37-40dee1cc1e44
Autor:
James Brady, Angelia Viley, Pachai Natarajan, Rama Shivakumar, Madhusudan V. Peshwa, Cornell Allen, Linhong Li, Meg Duskin
Publikováno v:
Pharmaceutical Bioprocessing. 3:463-470
In the next 5–10 years we could see cellular-based pharmaceuticals, or cell therapy, meeting the unmet medical needs of thousands of people. How this therapy will meet these needs depends on the ability of researchers and manufacturers to successfu
Autor:
Leisha A. Emens, Angelia Viley, Pachai Natarajan, Linhong Li, Madhusudan Peshwa, Xuequn Xu, Ying Ma, Chien Fu Hung, Qiu Jin, Cornell Allen, Rama Shivakumar
Publikováno v:
Human gene therapy. 29(5)
CD19-targeted chimeric antigen receptor (CAR) engineered T/natural killer (NK)-cell therapies can result in durable clinical responses in B-cell malignancies. However, CAR-based immunotherapies have been much less successful in solid cancers, in part
Autor:
Angelia Viley, Lawrence A. Wolfraim, Masashi Takahara, Madhusudan V. Peshwa, Mie Nieda, Ryuji Maekawa, Linda N. Liu, Rama Shivakumar
Publikováno v:
International Immunopharmacology. 15:488-497
Recent commercial approval of cancer vaccine, demonstrating statistically significant improvement in overall survival of prostate cancer patients has spurred renewed interest in active immunotherapies; specifically, strategies that lead to enhanced b
Autor:
Madhusudan V. Peshwa, Cornell Allen, Stephanie Feller, Sergey Dzekunov, Hiroyuki Fujisaki, Lawrence A. Wolfraim, Linhong Li, Joseph C. Fratantoni, Linda N. Liu, Dario Campana, Rama Shivakumar, Nicholas Chopas
Publikováno v:
Cancer Gene Therapy. 17:147-154
Natural killer (NK) cells hold promise for cancer therapy. NK cytotoxicity can be enhanced by expression of chimeric antigen receptors that re-direct specificity toward target cells by engaging cell surface molecules expressed on target cells. We dev
Autor:
Linhong Li, William E. Fogler, Stephanie Feller, Joseph C. Fratantoni, Linda N. Liu, Jonathan M. Weiss, Rama Shivakumar, Art D. Hanson
Publikováno v:
Cancer Gene Therapy. 11:346-353
Using a nonviral, electroporation-based gene transfection approach, we demonstrate the efficient and consistent transfection of two poorly immunogenic tumor cell lines: B16F10 melanoma and renal carcinoma (RENCA). Three genes, IL-12, angiostatin (AS)
Autor:
Rama Shivakumar, Stephanie Feller, Linhong Li, John W. Holaday, Cornell Allen, Sergey Dzekunov, Linda N. Liu, Joseph C. Fratantoni, Jonathan M. Weiss, Vin Singh
Publikováno v:
Technology in Cancer Research & Treatment. 1:341-349
Electroporation is widely used to transfect and load cells with various molecules. Traditional electroporation using a static mode is typically restricted to volumes less than 1 mL, which limits its use in clinical and industrial bioprocessing applic
Autor:
Madhusudan V. Peshwa, Angelia Viley, Cornell Allen, Leisha A. Emens, Linhong Li, Rama Shivakumar, Chien Fu Hung, Xuequn Xu, Pachai Natarajan, Ying Ma, Qiu Jin
Publikováno v:
Cancer Research. 77:3748-3748
CD19-targeted chimeric antigen receptor (CAR)-engineered T/NK-cell therapies can result in durable clinical responses in B-cell malignancies. However, CAR-based immunotherapies have been less successful in solid cancers. This is partly due to specifi
Autor:
Jeffrey B. Travers, Antoinette F. Hood, Christina Derstine, Alastair J. King, Bruce Diaz, David R. Williams, D. Wade Clapp, Mark S. Marshall, David A. Ingram, Rama Shivakumar, Lucy Fisher, Mary Jo Wenning, Kelly Hiatt
Publikováno v:
The Journal of Experimental Medicine
Mutations in the NF1 tumor suppressor gene cause neurofibromatosis type I (NF1), a disease characterized by the formation of cutaneous neurofibromas infiltrated with a high density of degranulating mast cells. A hallmark of cell lines generated from